13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Mast Cell Infiltration Is Associated With Persistent Symptoms and Endoscopic Abnormalities Despite Resolution of Eosinophilia in Pediatric Eosinophilic Esophagitis

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          OBJECTIVES:

          Mast cells (MCs) are increased in eosinophilic esophagitis (EoE). Endoscopic abnormalities, symptoms, and epithelial changes can persist after treatment despite a reduction of esophageal eosinophilia. It is unknown whether this could be due to persistent MC infiltration. We aimed to determine whether patients with histologically inactive (HI) EoE (defined as <15 eosinophils per high-powered field) with persistent symptoms, endoscopic, or epithelial abnormalities after treatment have increased MCs.

          METHODS:

          Secondary analysis of prospective data from 93 children with EoE undergoing post-treatment endoscopy between 2011 and 2015. Thirty-five non-EoE controls were included. Immunohistochemistry for tryptase, an MC marker, was performed on mid and distal esophageal biopsies. Total and degranulated intraepithelial MCs per high-powered field (MC/hpf) were quantified. Symptoms and endoscopic findings were recorded at time of endoscopy. MC/hpf were compared between HI-EoE and control, and among HI-EoE based on endoscopic and histologic findings, and symptoms. Nine clinical remission (CR) patients were identified, with absence of endoscopic abnormalities and symptoms.

          RESULTS:

          MC/hpf were increased in HI-EoE compared with control (17 ± 11 vs 8 ± 6, P < 0.0). Patients with persistent endoscopic abnormalities had increased total (20 ± 12 vs 13 ± 10, P = 0.001) and degranulated (8 ± 6 vs 5 ± 4, P = 0.002) MC/hpf, with no difference in eosinophils. MC/hpf predicted furrowing (odds ratio = 1.06, P = 0.01) and rings (odds ratio = 1.05, P = 0.03) after controlling for treatment type, proton-pump inhibitor, eosinophils, and duration of therapy. Patients with persistent basal zone hyperplasia and dilated intercellular spaces had increased MC/hpf. Eosinophils were weakly correlated with MC/hpf in the mid ( r = 0.30, P < 0.001) and distal ( r = 0.29, P < 0.001) esophagus. Clinical remission patients had lower MC/hpf compared with patients with persistent symptoms and/or endoscopic abnormalities.

          DISCUSSION:

          MC density is increased in patients with endoscopic and epithelial abnormalities, as well as a few symptoms, despite resolution of esophageal eosinophilia after treatment. This association warrants further study to ascertain whether MCs play an eosinophil independent role in EoE.

          Related collections

          Author and article information

          Journal
          0421030
          426
          Am J Gastroenterol
          Am. J. Gastroenterol.
          The American journal of gastroenterology
          0002-9270
          1572-0241
          12 September 2020
          February 2020
          15 September 2020
          : 115
          : 2
          : 224-233
          Affiliations
          [1 ]Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois, USA;
          [2 ]Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA;
          [3 ]Division of Gastroenterology, Department of Pediatrics, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, USA;
          [4 ]Department of Pathology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Illinois, USA;
          [5 ]Center for Esophageal Diseases and Swallowing, Division of Gastroenterology & Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA;
          [6 ]Division of Allergy & Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA;
          [7 ]Current affiliation: Immunology & Inflammation Therapeutic Area, Sanofi, USA.
          Author notes

          Specific author contributions: S.M.B.: data acquisition; data analysis; data interpretation; manuscript drafting; and critical revision. A.F.K.: data acquisition; data interpretation; manuscript drafting; and critical revision. N.C.A.: data acquisition and critical revision. M.-Y-W.: data acquisition. K.A.: data acquisition. H.M.-A.: data acquisition. E.S.D.: data interpretation and critical revision. P.J.B.: study concept; data interpretation; and manuscript revision. B.K.W.: manuscript drafting; data interpretation; and critical revision. J.B.W.: study concept; study design; data acquisition; data analysis; data interpretation; manuscript drafting; critical revision; and study supervision.

          Correspondence: Joshua B. Wechsler, MD. JWechsler@ 123456luriechildrens.org .
          Article
          PMC7491279 PMC7491279 7491279 nihpa1627270
          10.14309/ajg.0000000000000474
          7491279
          31913192
          47a3cde2-3ca3-4fc2-97d1-b1f2f067920f
          History
          Categories
          Article

          Comments

          Comment on this article